Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: Relation to fetal and maternal characteristics and pregnancy outcomes

Fetal Diagnosis and Therapy

Volumn 33, Issue 4, 2013, Pages 215-223

  Poon, L C Y ^a   Musci, T ^c   Song, K ^c   Syngelaki, A ^a   Nicolaides, K H ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c Ariosa Diagnostics   (United States)

Author keywords

Cell free fetal DNA; Cell free maternal DNA; First trimester screening; Preeclampsia; Preterm birth; Small for gestational age

Indexed keywords

CELL FREE DNA; CHORIONIC GONADOTROPIN; DNA; PREGNANCY ASSOCIATED PLASMA PROTEIN A; UNCLASSIFIED DRUG; CELL FREE FETAL DNA; CELL FREE MATERNAL DNA;

ADULT; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CHORION VILLUS SAMPLING; ETHNICITY; FEMALE; FETUS; FETUS BLOOD; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MATERNAL BLOOD; MATERNAL PLASMA; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PULSATILE FLOW; RNA TRANSLATION; SMALL FOR DATE INFANT; SMOKING; TRISOMY 18; TRISOMY 21; UTERINE ARTERY; UTERUS BLOOD FLOW; AFRICAN CARIBBEAN; CAUCASIAN; CHROMOSOME; CONTROLLED STUDY; EAST ASIAN; FETUS OUTCOME; PREVALENCE; SPONTANEOUS PRETERM BIRTH;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; DNA; EARLY DIAGNOSIS; FEMALE; FETAL GROWTH RETARDATION; HUMANS; PLACENTATION; PLASMA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PREMATURE BIRTH; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES; PULSATILE FLOW; UTERINE ARTERY; WEIGHT LOSS;

EID: 84878445851     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000346806     Document Type: Article

References (45)

1. Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, Chan KC, Lun FM, Go AT, Lau ET, To WW, Leung WC, Tang RY, Au-Yeung SK, Lam H, Kung YY, Zhang X, van Vugt JM, Minekawa R, Tang MH, Wang J, Oudejans CB, Lau TK, Nicolaides KH, Lo YM: Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011; 342:c7401.
2. Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, Lu V, McCullough R, Mc-Carthy E, Nygren AO, Dean J, Tang L, Hutchison D, Lu T, Wang H, Angkachatchai V, Oeth P, Cantor CR, Bombard A, van den Boom D: Noninvasive detection of fetal trisomy by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011; 204: 205. e1-e11.
3. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Deciu C, Grody WW, Nelson SF, Canick JA: DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011; 13: 913-920.
4. Sehnert AJ, Rhees B, Comstock D, de Feo E, Heilek G, Burke J, Rava RP: Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cellfree fetal DNA from maternal blood. Clin Chem 2011; 57: 1042-1049.
5. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH: Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206: 322. e1-e5.
6. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP: Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012; 119: 890-901.
7. Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB, Rodriguez MH, Williams J 3rd, Mitchell ME, Adair CD, Lee H, Jacobsson B, Tomlinson MW, Oepkes D, Hollemon D, Sparks AB, Oliphant A, Song K: Non-invasive chromosomal evaluation (NICE) study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 207: 137. e1-e8.
8. Sparks AB, Struble CA, Wang ET, Song K, Oliphant A: Optimized non-invasive evaluation of fetal aneuploidy risk using cell-free DNA from maternal blood. Am J Obstet Gynecol 2012; 206: 319. e1-e9.
9. Nicolaides KH, Syngelaki A, Birdir C, Touzet G, Ashoor G: Noninvasive prenatal testing for fetal trisomies in an average-risk population. Am J Obstet Gynecol 2012; 207: 374. e1-e6.
10. Nicolaides KH: Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31: 7-15.
11. Ashoor G, Syngelaki A, Poon LCY, Rezende JC, Nicolaides KH: Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol 2013;41:26-32.
12. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH: First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009; 33: 23-33.
13. Lo YM, Leung TN, Tein MS, et al: Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999; 45: 184-188.
14. Zhong XY, Laivuori H, Livingston JC, et al: Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am J Obstet Gynecol 2001; 184: 414-419.
15. Farina A, Sekizawa A, Rizzo N, et al: Cell-free fetal DNA (SRY locus) concentration in maternal plasma is directly correlated to the time elapsed from the onset of preeclampsia to the collection of blood. Prenat Diagn 2004; 24: 293-297.
16. Smid M, Galbiati S, Lojacono A, et al: Correlation of fetal DNA levels in maternal plasma with Doppler status in pathological pregnancies. Prenat Diagn 2006; 26: 785-790.
17. Nicolaides KH: Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183-196.
18. Robinson HP, Fleming JE: A critical evaluation of sonar crown rump length measurements. Br J Obstet Gynaecol 1975; 82: 702-710.
19. Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH: Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-weeks. Prenat Diagn 2011; 31: 90-102.
20. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH: A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008; 31: 376-383.
21. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH: Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of preeclampsia. Ultrasound Obstet Gynecol 2007; 30: 742-749.
22. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH: First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493-502.
23. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX-XIV.
24. Poon LC, Volpe N, Muto B, Syngelaki A, Nicolaides KH: Birthweight with gestation and maternal characteristics in live births and stillbirths. Fetal Diagn Ther 2012; 32: 156-165.
25. Sparks A, Wang E, Struble C, et al: Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012; 32: 1-7.
26. Ashoor G, Poon L, Syngelaki A, Mosimann B, Nicolaides KH: Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: effect of maternal and fetal factors. Fetal Diagn Ther 2012; 31: 237-243.
27. Zdravkovic T, Genbacev O, McMaster MT, Fisher SJ: The adverse effects of maternal smoking on the human placenta: a review. Placenta 2005; 26:S81-S86.
28. Jauniaux E, Burton GJ: The effect of smoking in pregnancy on early placental morphology. Obstet Gynecol 1992; 79: 645-648.
29. Carbillon L, Challier JC, Alouini S, Uzan M, Uzan S: Uteroplacental circulation development: Doppler assessment and clinical importance. Placenta 2001; 22: 795-799.
30. Anker P, Mulcahy H, Chen XQ, Stroun M: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999; 18: 65-73.
31. Bret L, Lule J, Alary C, Appolinaire-Pilipenko S, Pourrat JP, Fournie GJ: Quantitation of blood plasma DNA as an index of in vivo cytotoxicity. Toxicology 1990; 61: 283-292.
32. Holdenrieder S, Stieber P, Forg T, Kuhl M, Schulz L, Busch M, et al: Apoptosis in serum of patients with solid tumours. Anticancer Res 1999; 19: 2721-2724.
33. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD: Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998; 17: 89-97.
34. Haghiac M, Vora NL, Basu S, Johnson KL, Presley L, Bianchi DW, Mouzon SH: Increased death of adipose cells, a path to release cell-free DNA into systemic circulation of obese women. Obesity (Silver Spring) 2012; 20: 2213-2219.
35. Levine RJ, Qian C, Leshane ES, et al: Two stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol 2004; 190: 707-713.
36. Crowley A, Martin C, Fitzpatrick P, et al: Free fetal DNA is not increased before 22 weeks in intrauterine growth restriction or pre-eclampsia. Prenat Diagn 2007; 27: 174-179.
37. Sifakis S, Zaravinos A, Maiz N, et al: First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol 2009; 201: 472. e1-e7.
38. Illanes S, Parra M, Serra R, Pino K, Figueroa-Diesel H, Romero C, Arraztoa JA, Michea L, Soothill PW: Increased free fetal DNA levels in early pregnancy plasma of women who subsequently develop preeclampsia and intrauterine growth restriction. Prenat Diagn 2009; 29: 1118-1122.
39. Alberry MS, Maddocks DG, Hadi MA, Metawi H, Hunt LP, Abdel-Fattah SA, Avent ND, Soothill PW: Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. Am J Obstet Gynecol 2009; 200: 98. e1-e6.
40. Sekizawa A, Jimbo M, Saito H, Iwasaki M, Matsuoka R, Okai T, Farina A: Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction. Am J Obstet Gynecol 2003; 188: 480-484.
41. Bianchi DW: Fetal DNA in maternal plasma: the plot thickens and the placental barrier thins. Am J Hum Genet 1998; 62: 763-764.
42. Farina A, LeShane ES, Romero R, et al: High levels of fetal cell-free DNA in maternal serum: a risk factor for spontaneous preterm delivery. Am J Obstet Gynecol 2005; 193: 421-425.
43. Leung TN, Zhang J, Lau TK, Hjelm NM, Lo YM: Maternal plasma fetal DNA as a marker for preterm labour. Lancet 1998; 352: 1904-1905.
44. Jakobsen TR, Clausen FB, Rode L, Dziegiel MH, Tabor A: High levels of fetal DNA are associated with increased risk of spontaneous preterm delivery. Prenat Diagn 2012; 32: 840-845.
45. Illanes S, Gomez R, Fornes R, et al: Free fetal DNA levels in patients at risk of preterm labour. Prenat Diagn 2011; 31: 1082-1085.